The over-arching goal of the Healthy Aging and Senile Dementia (HASD) study is to determine the factors that signal the imminent development of symptomatic Alzheimer disease (AD) in cognitively normal older adults. In pursuing this goal, HASD also will examine whether these predictive factors differ between African Americans and non-Hispanic whites, are influenced by sleep, or might be offset by genetic variants that protect against developing symptomatic AD. Finally, HASD will evaluate a novel method of assessing cognitive performance in naturalistic settings via a smartphone application. To accomplish these goals, HASD will assess and follow a richly phenotyped cohort that includes both cognitively normal older adults (~75%) and those with early-stage symptomatic AD (~25%). The longitudinal assessment protocol includes standard and novel clinical and cognitive measures, a six-day in-home sleep study, magnetic structural imaging studies of the brain, positron emission tomography studies of the brain to reveal the cerebral hallmarks of AD, amyloid-beta plaques and tau deposition, and examination of blood for genetic studies and of cerebrospinal fluid for levels of amyloid-beta and tau. Five Cores (Administration, Clinical, Biostatistics, Neuropathology [includes the Biofluids Laboratory], and Imaging) will support four Projects that carry out the scientific aims of HASD: Project 1: ?Characterization of Molecular Biomarker Profiles of AD throughout its Pathobiological Continuum? Project 2: ?Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer Disease? Project 3: ?Dissecting the Genetic Architecture of Resilience? Project 4: ?Smartphone-Based `Burst' Cognitive Assessments?
The over-arching goal of the Healthy Aging and Senile Dementia (HASD) study is to determine those factors that signal the imminent development of Alzheimer disease (AD) in cognitively normal older adults. In pursuing this goal, HASD also will examine whether these predictive factors differ between African Americans and non- Hispanic whites, are influenced by sleep, or might be offset by genetic variants that protect against developing symptomatic AD. Finally, HASD will evaluate a novel method of assessing cognitive performance in naturalistic settings via a smartphone application.
|Ibanez, Laura; Dube, Umber; Davis, Albert A et al. (2018) Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Front Neurosci 12:230|
|Schultz, Stephanie A; Gordon, Brian A; Mishra, Shruti et al. (2018) Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiol Aging 72:177-185|
|Broce, Iris; Karch, Celeste M; Wen, Natalie et al. (2018) Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med 15:e1002504|
|Javaherian, Kavon; Newman, Brianne M; Weng, Hua et al. (2018) Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. Alzheimer Dis Assoc Disord :|
|Liao, Fan; Li, Aimin; Xiong, Monica et al. (2018) Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest 128:2144-2155|
|Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95|
|Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :|
|Islam, Jyoti; Zhang, Yanqing (2018) Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks. Brain Inform 5:2|
|Strain, Jeremy F; Smith, Robert X; Beaumont, Helen et al. (2018) Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. Neurology 91:e313-e318|
|Roe, Catherine M; Ances, Beau M; Head, Denise et al. (2018) Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain 141:3233-3248|
Showing the most recent 10 out of 911 publications